Nurexone Biologic【NRX】銘柄情報

Nurexone Biologic Inc (NRX) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.56

( - )

買値

0.56

売値

0.58

出来高

1,021

0.56 日の範囲 0.56

0.51 52 週間の範囲 1.14

時価総額

51.546M

前日終値

0.56

始値

0.56

時刻

1000

0.56

最終取引時間

22:32:16

財務取引量

VWAP

平均取引量 (3 か月)

$ 18,436

発行済株式数

92,045,848

配当利回り

PER

-5.05

1 株当たり利益 (EPS)

-0.08

歳入

純利益

-6.47M

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toron... NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

nurexone.com

本社

Toronto, Canada

設立

2026

Nurexone Biologic Inc is listed in the Healthcare sector of the トロントベンチャー取引所 with ticker NRX. The last closing price for Nurexone Biologic was $0.56. Over the last year, Nurexone Biologic shares have traded in a share price range of $ 0.51 to $ 1.14.

Nurexone Biologic currently has 92,045,848 shares in issue. The market capitalisation of Nurexone Biologic is $51.55 million. Nurexone Biologic has a price to earnings ratio (PE ratio) of -5.05.

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

Meet the micro-cap biotech company reinventing regenerative medicine

It’s a well-known and almost quaint fact that the human body is capable of regeneration. When we suffer a minor scrape or a cut, a little...

Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX...

NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026

Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone...

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone...

NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB:...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.01	1.81818181818	0.55	0.6	0.54	8774	0.55398915	CS
4	-0.05	-8.19672131148	0.61	0.66	0.51	17440	0.5631468	CS
12	-0.1	-15.1515151515	0.66	0.67	0.51	16134	0.59655302	CS
26	-0.1	-15.1515151515	0.66	0.7	0.51	19788	0.62456295	CS
52	-0.14	-20	0.7	1.14	0.51	35995	0.77874664	CS
156	0.285	103.636363636	0.275	1.19	0.185	44244	0.73093847	CS
260	-0.24	-30	0.8	1.19	0.1	34443	0.71597755	CS

NRX - Frequently Asked Questions (FAQ)

What is the current Nurexone Biologic Inc share price?

The current share price of Nurexone Biologic Inc is $ 0.56

How many Nurexone Biologic Inc shares are in issue?

Nurexone Biologic Inc has 92,045,848 shares in issue

What is the market cap of Nurexone Biologic Inc?

The market capitalisation of Nurexone Biologic Inc is CAD 51.55M

What is the 1 year trading range for Nurexone Biologic Inc share price?

Nurexone Biologic Inc has traded in the range of $ 0.51 to $ 1.14 during the past year

What is the PE ratio of Nurexone Biologic Inc?

The price to earnings ratio of Nurexone Biologic Inc is -5.05

What is the registered address of Nurexone Biologic Inc?

The registered address for Nurexone Biologic Inc is 1 Adelaide Street East, Toronto, Ontario, M5C 2V9

What is the Nurexone Biologic Inc website address?

The website address for Nurexone Biologic Inc is nurexone.com

Which industry sector does Nurexone Biologic Inc operate in?

Nurexone Biologic Inc operates in the Biotechnology & Life Sciences sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Nurexone Biologic Inc (NRX)

Nurexone Biologic Inc (NRX) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Nurexone Biologic Inc について

NRX 最新ニュース

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

Meet the micro-cap biotech company reinventing regenerative medicine

Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology

NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

Meet the micro-cap biotech company reinventing regenerative medicine

Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

NRX - Frequently Asked Questions (FAQ)

NRX 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

ADVFNに参加する理由

プロトレーダー向けの高機能ツール

広告を削除する